Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor to discuss the company’s innovative cancer treatments with the biotech company having a range of targeting therapies and their next generation CAR-T treatment called OmniCAR.
Watch the full interview below.